Literature DB >> 24868027

Enhancing therapeutic decision making when options abound: toxicities matter.

Nicole M Kuderer1, Antonio C Wolff2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24868027     DOI： 10.1200/JCO.2014.55.1903

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.

Authors:  Molly McFatrich; Jennifer Brondon; Nicole R Lucas; Pamela S Hinds; Scott H Maurer; Jennifer W Mack; David R Freyer; Shana S Jacobs; Justin N Baker; Catriona Mowbray; Mian Wang; Sharon M Castellino; Allison Barz Leahy; Bryce B Reeve
Journal:  Cancer       Date:  2019-09-25       Impact factor: 6.860

2.  Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation.

Authors:  Rifaquat Rahman; Paul J Catalano; David A Reardon; Andrew D Norden; Patrick Y Wen; Eudocia Q Lee; Lakshmi Nayak; Rameen Beroukhim; Ian F Dunn; Alexandra J Golby; Mark D Johnson; E Antonio Chiocca; Elizabeth B Claus; Brian M Alexander; Nils D Arvold
Journal:  J Neurooncol       Date:  2015-06-02       Impact factor: 4.130

Review 3.  Mitigating acute chemotherapy-associated adverse events in patients with cancer.

Authors:  Nicole M Kuderer; Aakash Desai; Maryam B Lustberg; Gary H Lyman
Journal:  Nat Rev Clin Oncol       Date:  2022-10-11       Impact factor: 65.011

4.  Measurement of chemotherapy-induced alopecia-time to change.

Authors:  C J G van den Hurk; J Winstanley; A Young; F Boyle
Journal:  Support Care Cancer       Date:  2015-02-10       Impact factor: 3.603

5.  Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.

Authors:  Sarah Knerr; Elaine Y Hu; Steven B Zeliadt
Journal:  EGEMS (Wash DC)       Date:  2017-03-13

6.  Use and misuse of common terminology criteria for adverse events in cancer clinical trials.

Authors:  Sheng Zhang; Fei Liang; Ian Tannock
Journal:  BMC Cancer       Date:  2016-07-04       Impact factor: 4.430

7.  Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.

Authors:  Fan Zhang; RuiXia LingHu; XingYang Zhan; Ruisheng Li; Fan Feng; Xudong Gao; Lei Zhao; Junlan Yang
Journal:  Oncotarget       Date:  2017-05-24

8.  The use of and adherence to CTCAE v3.0 in cancer clinical trial publications.

Authors:  Sheng Zhang; Qiang Chen; Qing Wang
Journal:  Oncotarget       Date:  2016-10-04

Review 9.  Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

Authors:  Syril D Pettit; Rebecca Kirch
Journal:  Cardiooncology       Date:  2018-06-15

10.  Incidence and clinical course of septic shock in neutropenic patients during chemotherapy for gynecological cancers.

Authors:  Jigeun Yoo; Yuyeon Jung; Jung Hwan Ahn; Youn Jin Choi; Keun Ho Lee; Sooyoung Hur
Journal:  J Gynecol Oncol       Date:  2020-09       Impact factor: 4.401
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.